There is growing interest in the development of drugs that are effective in controlling cough. 1 However, we feel that attention should be paid not only to efficacy but also to the safety of such drugs, particularly when they are being administered to patients with respiratory disorders. The cough motor pattern originates from the neuronal pool that also generates the eupnoeic respiratory rhythm, 2, 3 and most of the widely used antitussive drugs act centrally. Thus, it should be questioned whether their pharmacologic effect is devoid of the potential risk of ventilatory disturbances, since they may also depress the physiological responses to stimuli that activate breathing. Of note, the centrally acting antitussive agent codeine has been reported to depress the central response to hypercapnia more markedly in male subjects than in female subjects 4 ; however, this more pronounced depressant effect by codeine in female subjects turned out to actually reflect differences in smoking habits rather than sex. 4 Years ago, Read 5 14 Thus, in agreement with the current understanding of the chronic cough paradigm, all patients examined fit the criteria for classification into the so-called cough hypersensitivity syndrome. 15 All patients were free of any chronic treatment for their cough at the time of the study.
This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Azienda Ospedaliero Universitaria Careggi, Florence, Italy (approval: AOUC-001-2013; EudraCT 2013-004735-68). All adult participants provided written informed consent to participate in this study.
Protocol and Recording Procedures
This study was performed in a single-blind crossover fashion (Fig 1) . Under control conditions (ie, in no-drug trials), the ventilatory responses to a standard CO 2 rebreathing test 5 were assessed in each patient. Subsequently, on each of three separate (48-72 h) occasions, after clinical assessment, patients were randomly administered a single oral dose of levodropropizine (60 mg [20 drops]), dihydrocodeine (30 mg [90 drops]), or placebo (20 drops of a multivitamin compound). The order of administration of the three agents was obtained by using an online software program (www.randomization. com), which creates random permutations of treatments for studies in which subjects are to receive all the treatments in random order. Two hours later, patients breathed a mixture of 93% oxygen and 7% CO 2 for 4 min. 5 The inspired air mixture was warmed and humidified and flowed through a 6 L reservoir bag past the inspiratory port of a twoway nonrebreathing balloon shutter occlusion valve (Hans Rudolph journal.publications.chestnet.org
No. 4). During 5 min of relaxed air breathing and during CO 2 rebreathing, we measured, on a breath-by-breath basis, the tidal volume (VT), the inspiratory time, the VT/inspiratory time (an index of respiratory drive), and the duration of the respiratory cycle (TT). 2 The _ VI and respiratory frequency (respiratory frequency, 60/TT) were subsequently calculated; the fractional end-tidal CO 2 (FETCO 2 ) was also monitored (Normocap CD 102; Datex). 2 In a subgroup of eight randomly selected patients, the value of mouth inspiratory pressure measured 0.1 s after mouth occlusion (P0.1), which is another index of respiratory drive, 8 was also recorded. In each set of four to eight breaths, the inspiratory line was silently and randomly closed during expiration by inflating the balloon. The mouth pressure during the following occluded inspiration was measured at a side port on the occlusion valve connected to a pressure transducer with a noncompliant catheter. Reported values of P0.1 were the mean of at least six measurements of occlusion pressure, the lowest and the highest values being discarded.
Data Analysis
Based on previous investigations, 16 the study, with a sample of 24 patients, was to have a > 80% statistical power of detecting a 10% between-treatment difference in CO 2 sensitivity, with a significance level of .05. The primary outcome of the study was the CO 2 sensitivity calculated as the slope of the _ VI/FETCO 2 . Comparisons of breathing pattern variables, P0.1 values, and slopes were performed by repeated-measure analysis of variance followed by Dunn tests. P < .05 was taken as significant.
Results
All patients completed the study; no adverse effect were reported by patients, except some discomfort caused by the hyperpnea that occurred during rebreathing. Individual mean values of baseline breathing pattern variables observed on each study day were similar and were not influenced by placebo or active agents ( Table 2) . Rebreathing consistently induced a marked increase (P < .01) in baseline _ VI, irrespective of the previously administered agent; these increases were proportional (r ¼ 0.98 AE 0.01) to FETCO 2 (Fig 2, Table 2 ) and were always within the normal range. 17 Analysis of the breathing pattern (Table 2) revealed that the ventilatory increases were mainly accounted for by a rise in VT and by less marked increases in respiratory frequency (Fig 2, Table 2 ). CO 2 sensitivity after levodropropizine and placebo administration was similar and higher (P < .05), respectively, than after dihydrocodeine administration (Fig 2) . In eight patients, P0.1 consistently increased significantly during rebreathing; however, compared with placebo and levodropropizine, these increases were less prominent (P < .05) following dihydrocodeine administration (Table 2) .
Discussion
The results demonstrate that levodropropizine does not affect the ventilatory response to CO 2 in patients with chronic cough, supporting the lack of any significant central neuronal respiratory action. Conversely, with a standard and safe dose of dihydrocodeine, we have established a difference in ventilatory response to CO 2 .
Since the vast majority (about 70%) of patients in our study were women, we believe it is inappropriate to attempt at evaluating any sex-related difference in the CO 2 ventilatory responses.
It has long been known that IV morphine administration profoundly depresses eupneic breathing, 18 and the journal.publications.chestnet.org neurophysiological mechanisms that subserve this inhibitory response have been reevaluated in more recent years. Indeed, animal studies have shown how sensory inputs to the brainstem reconfigure the pontomedullary respiratory central pattern generator so that normal respiration is converted to that of a cough motor pattern. [19] [20] [21] [22] Ionotropic glutamate receptors located in the caudal aspect of the nucleus tractus solitarii, especially those within the commissural subnucleus of the nucleus tractus solitarii, have been implicated in the mediation of the cough reflex evoked by the mechanical stimulation of the tracheobronchial tree in the rabbit. 23 Conversely, in the guinea pig, Canning and Mori 24 provided evidence for a more distributed termination of the cough receptor endings innervating the extrathoracic trachea within the nucleus tractus solitarii. Species differences may account, at least to some extent, for the different results between laboratories. Whatever the specific sites of termination of cough receptors within the nucleus tractus solitarii, it seems likely that various aspects of this region play an important role in the integration of peripheral inputs regulating the cough reflex, and therefore they could be the site of action of antitussive drugs. 25, 26 Notably, Bolser et al 25 demonstrated that intravertebral artery administration of opioids reduced, in a dosedependent manner, the number of coughing episodes and rectus abdominis burst amplitude during coughing induced by mechanical stimulation of cat trachea. In light of these studies, it seems well established that the respiratory medullary areas are also involved in cough mediation and that depression of respiratory neurons may occur following administration of cough suppressants.
The present findings further demonstrate the robustness and sensitivity of the CO 2 rebreathing method 5 and reliably demonstrate that levodropropizine does not have a central depressant action in subjects with chronic cough, normal CO 2 sensitivity, and no evidence of airway obstruction. In addition, the result is in keeping with previous observations 8 
obtained in patients with
COPD showing no significant change in CO 2 sensitivity after therapeutic doses of levodropropizine. In this study, 8 however, no comparisons were done with central antitussive drugs nor were attempts made at detecting changes in the pattern of breathing, possibly pointing at more subtle effects on respiratory control by levodropropizine. In this study, we demonstrated that, at variance with dihydrocodeine, which affects both the frequency and the volume components of the breathing pattern, levodropropizine does not influence breathing pattern or _ VI compared with control conditions.
The antitussive action of levodropropizine is not fully characterized, but it seems independent of bronchodilation or muscarinic receptor antagonism, 27 since at doses that inhibit induced coughing, it does not block methacholine-induced bronchoconstriction in asthma. 27 Previous animal studies suggest that its antitussive action may depend on blockade of a large proportion of pulmonary C fibers. 11 Most importantly, however, the results confirm the lack of any detectable action by levodropropizine, but not dihydrocodeine, at the level of the human respiratory network.
This was a single-blind study, that is, patients were unaware of the administered agents. However, blinding becomes less important for reducing observer bias, as the outcomes are assessed objectively, thus leaving little opportunity for bias. 28 In conclusion, levodropropizine does not affect the ventilatory response to CO 2 in subjects with chronic cough and normal CO 2 sensitivity; this suggests the lack of any depressant central action. We propose that the clinical study of respiratory control during CO 2 rebreathing should routinely be used when one needs to investigate the central respiratory effects of drugs, especially antitussive agents.
